Operational tolerance in clinical liver transplantation: Emerging developments

Transplant Immunology

Volumn 17, Issue 2, 2007, Pages 108-113

  Tisone, Giuseppe ^a   Orlando, Giuseppe ^a   Angelico, Mario ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Immunosuppression; Tolerance

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; CD4 ANTIGEN; CYCLOSPORIN A; IMMUNOGLOBULIN ANTIBODY; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN; NATURAL KILLER CELL RECEPTOR; RIBAVIRIN; TACROLIMUS;

ACUTE GRAFT REJECTION; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHRONIC GRAFT REJECTION; DRUG DOSE REDUCTION; DRUG INDUCED CANCER; DRUG WITHDRAWAL; EDITORIAL; GENE EXPRESSION PROFILING; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INFECTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOTHERAPY; NATURAL KILLER CELL; NONHUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TRANSPLANTATION TOLERANCE;

HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; TRANSPLANTATION TOLERANCE; WITHHOLDING TREATMENT;

EID: 33846928735     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2006.09.021     Document Type: Editorial

References (52)

1. Starzl T.E. The mystic of organ transplantation. J Am Coll Surg 201 2 (2005) 160-170
2. Dharnidharka V.R., Stablein D.M., and Harmon W.E. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transpl 4 (2004) 384-389
3. Dantal J., and Soulillou J.P. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Eng J Med 352 13 (2005) 1371-1373
4. Haagsma E.B., Hagens V.E., Schaapveld M., van den Berg A.P., de Vries E.G., Klompmaker I.J., et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 34 1 (2001) 84-91
5. Dantal J., Hourmant M., Cantarovich D., Giral M., Blancho G., Dreno B., et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 351 9103 (1998) 623-628
6. Coulson M.T., Jablonski P., Howden B.O., Thomson N.M., and Stein A.N. Beyond operational tolerance: effect of ischemic injury on development of chronic damage in renal grafts. Transplantation 80 3 (2005) 353-360
7. Ashton-Chess J., Brouard S., and Soulillou J.P. Is clinical tolerance realistic in the next decade?. Transpl Int 19 7 (2006) 539-548
8. Calne R.Y. Prope tolerance: the future of organ transplantation-from the laboratory to the clinic. Transplantation 77 6 (2004) 930-932
9. Cortesini R., and Suciu-Foca N. The concept of "partial" clinical tolerance. Transpl Immunol 13 2 (2004) 101-104
10. Filipponi F., Pisati R., Cavicchini G., Ulivieri M.I., Ferrara R., and Mosca F. Cost and outcome analysis and cost determinants of liver transplantation in a European national health service hospital. Transplantation 75 10 (2003) 1731-1736
11. Karam V.H., Gasquet I., Delvart V., Hiesse C., Dorent R., Danet C., et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation 76 12 (2003) 1699-1704
12. Galbraith C.A., and Hathaway D. Long-term effects of transplantation on quality of life. Transplantation 77 9 Suppl (2004) S84-S87
13. Monaco A.P. The beginning of clinical tolerance in solid organ allografts. Exp Clin Transplant 2 1 (Jun 2004) 153-161
14. Sanchez-Fueyo A., and Strom T.B. Immunological tolerance and liver transplantation. J Hepatol 41 5 (2004) 698-705
15. Wang C., Sun J., Sheil A.G., McCaughan G.W., and Bishop G.A. A short course of methylprednisolone immunosuppression inhibits both rejection and spontaneous acceptance of rat liver allografts. Transplantation 72 1 (2001) 44-51
16. Mazariegos G.V., Reyes J., Marino I.R., Demetris A.J., Flynn B., Irish W., et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 63 2 (1997) 243-249
17. Ramos H.C., Reyes J., Abu-Elmagd K., Zeevi A., Reinsmoen N., Tzakis A., et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 59 2 (1995) 212-217
18. Devlin J., Doherty D., Thomson L., Wong T., Donaldson P., Portmann B., et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 27 4 (1998) 926-933
19. Girlanda R., Rela M., Williams R., O'Grady J.G., and Heaton N.D. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc 37 4 (2005) 1708-1709
20. Takatsuki M., Uemoto S., Inomata Y., Sakamoto S., Hayashi M., Ueda M., et al. Analysis of alloreactivity and intragraft cytokine profiles in living donor liver transplant recipients with graft acceptance. Transpl Immunol 8 4 (2001) 279-286
21. Takatsuki M., Uemoto S., Inomata Y., Egawa H., Kiuchi T., Fujita S., et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 72 3 (2001) 449-454
22. Li Y., Koshiba T., Yoshizawa A., Yonekawa Y., Masuda K., Ito A., et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 4 12 (2004) 2118-2125
23. Starzl T.E., Murase N., Abu-Elmagd K., Gray E.A., Shapiro R., Eghtesad B., et al. Tolerogenic immunosuppression for organ transplantation. Lancet 361 9368 (2003) 1502-1510
24. Starzl T.E., Murase N., Demetris A.J., Trucco M., Abu-Elmagd K., Gray E.A., et al. Lessons of organ-induced tolerance learned from historical clinical experience. Transplantation 77 6 (2004) 926-929
25. Eason J.D., Cohen A.J., Nair S., Alcantera T., and Loss G.E. Tolerance: is it worth the risk?. Transplantation 79 9 (2005) 1157-1159
26. Miller J., Mathew J.M., and Esquenazi V. Toward tolerance to human organ transplants: a few additional corollaries and questions. Transplantation 77 6 (2004) 940-942
27. Knechtle S.J., and Burlingham W.J. Metastable tolerance in nonhuman primates and humans. Transplantation 77 6 (2004) 936-939
28. Strober S., Lowsky R.J., Shizuru J.A., Scandling J.D., and Millan M.T. Approaches to transplantation tolerance in humans. Transplantation 77 6 (2004) 932-936
29. Reding R., Gras J., Truong D.Q., Wieers G., and Latine D. The immunological monitoring of alloreactive responses in liver transplant recipients: a review. Liver Transpl 12 3 (2006) 373-383
30. Strom T.B. Is transplantation tolerable?. J Clin Invest 113 12 (2004) 1681-1683
31. Tisone G., Orlando G., Cardillo A., Palmieri G., Manzia T., Baiocchi L., et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 44 (2006) 702-709
32. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation?. J Hepatol 42 4 (2005) 448-456
33. Wiesner R.H., Sorrell M., Villamil F., and International Liver Transplantation Society Expert Panel. Report of the first international LT society expert panel consensus conference on LT and hepatitis C. Liver Transpl (2003)
34. Wang C., Sun J., Sheil A.G., McCaughan G.W., and Bishop G.A. A short course of methylprednisolone immunosuppression inhibits both rejection and spontaneous acceptance of rat liver allografts. Transplantation 72 1 (2001) 44-51
35. Sileri P., Schena S., Fukada J., Rastellini C., Pirenne J., Benedetti E., et al. Corticosteroids enhance hepatic injury following ischemia-reperfusion. Transplant Proc 33 7-8 (2001) 3712
36. Tisone G., Angelico M., Palmieri G., Pisani F., Anselmo A., Baiocchi L., et al. A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation. Transplantation 67 10 (1999) 1308-1313
37. Eren R., Landstein D., Terkieltaub D., Nussbaum O., Zauberman A., Ben-Porath J., et al. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 80 6 (2006) 2654-2664
38. Davis G.L., Nelson D.R., Terrault N., Pruett T.L., Schiano T.D., Fletcher C.V., et al. The Collaborative Antiviral Study Group. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 11 8 (2005) 941-949
39. Wang C.S., Ko H.H., Yoshida E.M., Marra C.A., and Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 6 7 (2006) 1586-1599
40. Heydtmann M., Freshwater D., Dudley T., Lai V., Palmer S., and Hubscher S. Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation. Am J Transplant 6 4 (2006) 825-833
41. Muzi F., Orlando G., Ielpo B., Anselmo A., Sabato Ceraldi S., de'Liguori Carino N., et al. Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting. Transplant Proc 37 4 (2005) 1705-1707
42. Triantos C., Samonakis D., Stigliano R., Thalheimer U., Patch D., and Burroughs A. Liver transplantation and hepatitis C virus: systematic review of antiviral therapy. Transplantation 79 3 (2005) 261-268
43. Roche B., and Samue D. Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis C. Transpl Int 17 12 (2005) 759-766
44. Rimola A., Londono M.C., Guevara G., Bruguera M., Navasa M., and Forns X. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 78 5 (2004) 686-691
45. Klatsky A.L., Morton C., Udaltsova N., and Friedman G.D. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 166 11 (2006) 1190-1195
46. Kirk A.D. Ethics in the quest for transplant tolerance. Transplantation 77 6 (2004) 947-951
47. Mazariegos G.V., Zahorchak A.F., Reyes J., Chapman H., Zeevi A., and Thomson A.W. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant 5 2 (2005) 314-322
48. Mazariegos G.V., Zahorchak A.F., Reyes J., Ostrowski L., Flynn B., Zeevi A., et al. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant 3 6 (2003) 689-696
49. Thomson A.W., Mazariegos G.V., Reyes J., Donnenberg V.S., Donnenberg A.D., Bentlejewski C., et al. Monitoring the patient off immunosuppression. Conceptual framework for a proposed tolerance assay study in liver transplant recipients. Transplantation 72 8 Suppl (2001) S13-S22
50. Martínez-Llordella M, Puig-Pey I, Ramoni M, Orlando G, Tisone G, Lerut J, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transpl, in press.
51. VanBuskirk A.M., VanBuskirk A.M., Burlingham W.J., Jankowska-Gan E., Chin T., Kusaka S., et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 106 7 (2000) 145-155
52. Martinez O.M., and Rosen H.R. Basic concepts in transplant immunology. Liver Transpl 11 4 (2005) 370-381